Adagene Inc. American Depositary Shares (ADAG) is a publicly traded Healthcare sector company. As of May 21, 2026, ADAG trades at $3.45 with a market cap of $223.99M and a P/E ratio of 0.00. ADAG moved -1.91% today. Year to date, ADAG is +93.82%; over the trailing twelve months it is +121.15%. Its 52-week range spans $1.30 to $4.75. Analyst consensus is strong buy with an average price target of $8.33. Rallies surfaces ADAG's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Adagene Adds 13-Drug Approval Veteran Peter Lebowitz to Boost ADG126 Strategy: Adagene added industry veteran Peter Lebowitz, MD, Ph.D., to its Scientific and Strategic Advisory Board. His record of 13 drug approvals and 12 FDA Breakthrough Therapy designations at J&J will inform ADG126’s clinical development and strategies for registration-enabling studies in microsatellite-stable colorectal cancer.
| Metric | Value |
|---|---|
| Price | $3.45 |
| Market Cap | $223.99M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.75 |
| 52-Week Low | $1.30 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
3 analysts cover ADAG: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.33.